Patents by Inventor Greg Dussor

Greg Dussor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule modulators of PAR2 and uses thereof
    Patent number: 11952379
    Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to a new class of small-molecules having a pyrazino-pyrimidine-dione (or related) structure which function as modulators (activators, inhibitors) of protease activated receptor type 2 (PAR2), and their use as therapeutics for the treatment of conditions involving PAR2 activity (e.g., asthma, chronic pain, cancer and/or vascular disorders).
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 9, 2024
    Assignees: Arizona Board of Regents on Behalf of the University of Arizona, Board of Regents, The University of Texas System
    Inventors: Scott A. Boitano, Josef Vagner, Theodore J. Price, Greg Dussor
  • Regulation of eIF4E activity for migraine therapy
    Patent number: 11925642
    Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: March 12, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Greg Dussor, Jacob E. Lackovic
  • REGULATION OF eIF4E ACTIVITY FOR MIGRAINE THERAPY
    Publication number: 20220110937
    Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 7, 2021
    Publication date: April 14, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Greg Dussor, Jacob E. Lackovic